Genelux (GNLX) Interest Coverage Ratio (2022 - 2023)
Genelux (GNLX) posted Interest Coverage Ratio of 126.36 for Q3 2023, up 43.79% on a QoQ basis from 224.79 in Q2 2023, and down 669.64% year-over-year from 22.18 in Q3 2022.
Powered by 
Analysis
Genelux (GNLX) Interest Coverage Ratio (2022 - 2023) Analysis & Trends
Genelux has reported Interest Coverage Ratio for 2 years, with the latest figure at 126.36 in Q3 2023.
- On a quarterly basis, Interest Coverage Ratio fell 669.64% year-over-year to 126.36 in Q3 2023; TTM through Dec 2023 was 7.61, a N/A change from a year earlier, with the FY2023 full-year figure at 7.67, down 192.62% from the prior year.
- Interest Coverage Ratio was 126.36 for Q3 2023 at Genelux, up from 224.79 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 22.18 in Q3 2022, with the low at 224.79 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -126.36 |
| Jun 30, 2023 | -224.79 |
| Mar 31, 2023 | -2.08 |
| Dec 31, 2022 | -10.63 |
| Sep 30, 2022 | 22.18 |